Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Revenue - Other Shares Issued Shares Outstanding Shares Outstanding Wages, Salaries and Other

Ratios

Senti Biosciences (SNTI) Long-Term Debt Issuances (2021)

Senti Biosciences has reported Long-Term Debt Issuances over the past 1 years, most recently at $250000.0 for Q4 2021.

For Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $250000.0; the TTM value through Sep 2023 reached $250000.0, down 66.67%, while the annual FY2022 figure was $5.2 million, N/A changed from the prior year.
Long-Term Debt Issuances for Q4 2021 was $250000.0 at Senti Biosciences, roughly flat from $250000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $250000.0 in Q2 2021 and troughed at $250000.0 in Q2 2021.